About
Andrew D. Dickinson is Gilead's Chief Financial Officer, overseeing the company's global finance, corporate development, information technology, operations and strategy organizations.
He joined Gilead in 2016 as head of the company's corporate development and strategy group, where he drove Gilead's licensing, partnership and acquisition transactions and guided investments into new areas. Before Gilead he was the global Co-Head of Healthcare Investment Banking at Lazard, and earlier served as General Counsel and Vice President of Corporate Development at Myogen Inc., which Gilead acquired in 2006.
Roles
Gilead Sciences, Inc.
Chief Financial Officer · Current role
2016–present
Gilead Sciences, Inc.
Head of Corporate Development and Strategy · Drove all of Gilead's licensing, partnership and acquisition transactions and guided investments into new areas.
—
Lazard
Global Co-Head of Healthcare Investment Banking
—
Myogen, Inc.
General Counsel and Vice President of Corporate Development · Myogen was acquired by Gilead in 2006.
—
Gilead Sciences, Inc.
Executive Vice President, Corporate Development and Strategy · Role held prior to appointment as CFO effective November 1, 2019.
—
External Roles
Sutter Health
Member, Board of Directors
—
Galapagos NV
Former Member, Board of Directors
—
Fosun Pharma / Kite joint venture (China)
Former Member, Board of Directors
—
Fixed Compensation
FY 2025
All other compensation
$70,979
Total compensation
$8,765,616
Performance Compensation
Data from FY 2025
Cash incentive
Annual cash incentive
$1,956,266
Stock awards
Also at Gilead Sciences, Inc.